Xtl Biopharmaceuticals (XTLB) Change in Intangibles (2013 - 2015)
Xtl Biopharmaceuticals (XTLB) posted quarterly Change in Intangibles of -$64000.0 for Q3 2015, down 481.82% on a QoQ basis from -$11000.0 in Q4 2013.
Xtl Biopharmaceuticals (XTLB) Change in Intangibles (2013 - 2015) Analysis & Trends
Xtl Biopharmaceuticals (XTLB) has reported Change in Intangibles for 2 consecutive years, with -$64000.0 the latest figure, recorded in Q3 2015.
- Quarterly Change in Intangibles changed N/A year-over-year to -$64000.0 in Q3 2015, while the trailing twelve-month figure through Dec 2015 was -$75000.0 (changed N/A YoY) and the FY2016 annual result came in at -$64000.0, changed 0.0% from the prior year.
- Change in Intangibles declined to -$64000.0 in Q3 2015 per XTLB's latest filing, from -$11000.0 in the prior quarter.
- Over the last five years, Change in Intangibles for XTLB reached as high as -$11000.0 in Q4 2013 and fell as low as -$73000.0 in Q1 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -66,508.31 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Xtl Biopharmaceuticals | 2.60 Bn | 2.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2015 | -64,000.00 |
| Sep 30, 2015 | -64,000.00 |
| Dec 31, 2013 | -11,000.00 |
| Dec 31, 2013 | -11,000.00 |
| Mar 31, 2013 | -73,000.00 |
| Mar 31, 2013 | -73,000.00 |